Can bicalutamide stop DHT from shrinking your hair follicles?

Hair loss, particularly androgenetic alopecia, is a common concern affecting both men and women. This condition is closely linked to the action of dihydrotestosterone (DHT), a hormone derived from testosterone that can lead to what is known as "shrinking" or miniaturization of hair follicles. This term refers to a gradual process where the follicles — structures in the skin where each hair grows — become smaller over time. As a result, the hairs they produce become thinner, shorter, and lighter in color, until they eventually stop growing altogether. Bicalutamide, a drug licensed for prostate cancer, is prescribed off-label by some dermatologists — mainly for women — on the reasoning that it blocks DHT at the follicle.

This article summarizes what the published evidence on bicalutamide for androgenetic alopecia does and does not show. Bicalutamide is a prescription-only medicine and is not approved for hair loss in any country.

What is Bicalutamide and How Does It Work?

Bicalutamide is a non-steroidal antiandrogen. The product label describes it as blocking the action of male sex hormones (androgens) at the androgen receptor, rather than acting as a steroid hormone itself. These receptors act like locks: when a hormone like DHT binds to them, it triggers a series of processes inside the cell. By occupying the lock (the receptor), bicalutamide prevents the hormone from exerting its effects. Unlike finasteride, which reduces how much DHT the body makes, bicalutamide does not lower circulating DHT. Instead, it competes with DHT at the receptor. In theory, this could help maintain the follicles at a healthy size and slow progressive thinning. That is a mechanism-based expectation, not a demonstrated outcome — the drug has never been tested for hair loss in a randomized controlled trial.

Scientific Evidence on the Use of Bicalutamide in Androgenetic Alopecia

Bicalutamide is not FDA-approved for treating hair loss, and the published evidence is small, retrospective and mostly in women.

A retrospective study published in 2020 in the Journal of the American Academy of Dermatology reviewed the safety of oral bicalutamide in women with female pattern hair loss. The study covered 316 patients and was a review of medical records rather than a trial. The authors reported that the drug was generally well tolerated in that cohort, with few side effects recorded. Because it was retrospective, with no control group and no randomization, it says more about tolerability in a specialist clinic than about how well the drug works. It measured safety, not hair regrowth.

Another retrospective study, published in 2022 in the same journal, evaluated 35 patients who developed hypertrichosis (hair growth in unwanted areas) while taking minoxidil. The authors reported that bicalutamide improved that unwanted growth. Again, the small sample and absence of a control group limit what can be concluded, and this outcome is about suppressing unwanted hair rather than about scalp regrowth.

A 2019 pilot study of oral bicalutamide in female pattern hair loss was published in Dermatologic Therapy by a trichology unit in Madrid. An earlier version of this article attributed a specific response rate and a direct safety comparison against flutamide to that pilot; neither could be confirmed from the published record, so both have been removed. A literature review dated 2025 was also cited here for the conclusion that bicalutamide is "effective" in women with signs of excess androgens; that citation could not be located in PubMed or at the publisher, so it and the conclusion drawn from it have been removed as well.

What is left is an honest summary: retrospective case series and a pilot study, in women, reporting acceptable tolerability and some reported improvement, with no randomized trial and no long-term outcome data.

Comparison with Other Treatments

The best-established treatments for androgenetic alopecia are finasteride and minoxidil. Finasteride inhibits 5-alpha reductase, the enzyme that converts testosterone into DHT, lowering DHT levels. Minoxidil does not act on hormones; it is thought to act on the follicle and its blood supply to extend the growth phase. Bicalutamide takes a different route — blocking the receptor rather than reducing the hormone.

Some prescribers consider it for women who cannot take, or have not responded to, other options. Trials of oral finasteride at the standard 1 mg dose in postmenopausal women did not show benefit, which is part of why anti-androgens such as spironolactone and bicalutamide are used off-label in women instead. Whether bicalutamide is better, worse or equivalent to those alternatives has not been tested head to head.

Safety Considerations and Side Effects

Bicalutamide is a prescription antiandrogen with real risks, and the studies above measured tolerability in supervised clinic settings, not safety in general use.

Pregnancy: bicalutamide is contraindicated in pregnancy and can harm a developing fetus. Anyone who could become pregnant should discuss reliable contraception with the prescriber before starting, and should not take it while pregnant or trying to conceive. Tablets must not be crushed, split or handled by someone who is pregnant or may become pregnant — the film coating exists to prevent exposure to the drug substance, and household members should not handle broken tablets.

Reported side effects include breast tenderness and breast enlargement, changes in liver enzyme levels, fatigue, hot flushes, and changes to the menstrual cycle. The most serious concern is liver injury: bicalutamide labelling carries a warning about hepatotoxicity, including rare cases of liver failure, and prescribers monitor liver function tests before and during treatment. Anyone using it should do so under medical supervision, with the blood tests the prescriber asks for, and should report yellowing of the skin or eyes, dark urine, persistent nausea or right-sided abdominal pain immediately.

Talk to a doctor or pharmacist before starting, stopping or combining bicalutamide.

User experience

Bicalutamide, a non-steroidal oral anti-androgen, is discussed as an off-label option for female pattern hair loss (FPHL), particularly by women who did not tolerate other therapies such as spironolactone. On Tressless, several users have shared personal experiences that show how and why it comes up. In one discussion, women compared spironolactone and bicalutamide for androgenic alopecia. Some users reported that while spironolactone reduced their shedding, it brought side effects such as reduced libido and frequent urination, and described bicalutamide as more tolerable for them. These are individual accounts, not trial results, and the people who post are not a representative sample.

Another post featured a 30-year-old woman who considered bicalutamide for androgenetic alopecia but was concerned about effects on muscle growth. Community members raised dutasteride, minoxidil and RU58841 in reply. Of those, dutasteride and minoxidil are licensed medicines used off-label or on-label for hair loss depending on the country, while RU58841 is an unapproved research chemical that has never completed human trials, is not available as a medicine, and has no established safety profile — it is not an equivalent alternative and is not something this site recommends.

In more severe cases — one user described androgenetic alopecia together with chronic telogen effluvium — bicalutamide was reported as one part of a regimen that also included finasteride, spironolactone, oral minoxidil and birth control. That user reported that only steroid injections temporarily slowed the shedding. Stacking prescription anti-androgens is a decision for a prescriber, not something to assemble from forum posts.

Another female user described difficulty obtaining a prescription, as her dermatologist declined to prescribe bicalutamide because of its off-label status, even after more conventional therapies had failed. That is a common experience and reflects genuine caution about an unlicensed indication rather than mere hesitancy.

On the published side, the picture is thinner than the community discussion suggests. The 2019 Dermatologic Therapy pilot study of oral bicalutamide in FPHL exists, but the response rate previously quoted here could not be verified and has been removed. A review formerly cited for the claim that bicalutamide "does not cross the blood-brain barrier" has also been removed: bicalutamide is described as peripherally selective, meaning limited central nervous system penetration, which is not the same as none.

Bicalutamide has also been tried by injection into the scalp (mesotherapy) in very small case series. Reported improvements were subtle and were not maintained at follow-up in the material available, and the numbers involved are too small to support any conclusion about whether it works or whether it is safe by that route. It is an experimental delivery method, not an established one. In short, bicalutamide is an off-label option that some dermatologists prescribe for women with androgen-related hair loss who do not tolerate other anti-androgens; the supporting evidence is early and uncontrolled, and access depends on the prescriber and local regulations.

Conclusion

Blocking the androgen receptor is a plausible way to counter the follicle miniaturization driven by DHT, and that is the reasoning behind prescribing bicalutamide off-label for hair loss. It does not lower DHT levels; it competes with DHT at the receptor. Whether that translates into preserved or regrown hair is not established. The published evidence is retrospective case series and a small pilot study, all in women, with no randomized controlled trial and no long-term data — and against that sits a prescription drug with hepatotoxicity monitoring requirements and a pregnancy contraindication. Anyone considering it should have that conversation with a doctor who will monitor them, not start it on their own.

References

• Ismail, F. F., Meah, N., Trindade de Carvalho, L., Bhoyrul, B., Wall, D., & Sinclair, R. (2020). Safety of oral bicalutamide in female pattern hair loss: A retrospective review of 316 patients. Journal of the American Academy of Dermatology, 83(5), 1478–1479. PMID 32213304. https://doi.org/10.1016/j.jaad.2020.03.034

• Moussa, A., Kazmi, A., Bokhari, L., & Sinclair, R. D. (2022). Bicalutamide improves minoxidil-induced hypertrichosis in female pattern hair loss: A retrospective review of 35 patients. Journal of the American Academy of Dermatology, 87(2), 488–490. PMID 34740752. https://doi.org/10.1016/j.jaad.2021.10.048

• Fernandez-Nieto, D., Saceda-Corralo, D., Rodrigues-Barata, R., Hermosa-Gelbard, A., Moreno-Arrones, O., Jimenez-Cauhe, J., Ortega-Quijano, D., & Vano-Galvan, S. (2019). Oral bicalutamide for female pattern hair loss: A pilot study. Dermatologic Therapy, 32(6), e13096. PMID 31579984. https://doi.org/10.1111/dth.13096